Tocagen Inc (NASDAQ:TOCA) issued its quarterly earnings results on Wednesday. The company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.02), Bloomberg Earnings reports. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million.

Shares of Tocagen (TOCA) traded down $0.22 during trading on Thursday, reaching $10.50. The company’s stock had a trading volume of 474,843 shares, compared to its average volume of 145,540. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.20 and a quick ratio of 7.20. Tocagen has a 52-week low of $8.60 and a 52-week high of $17.95.

A number of analysts have weighed in on TOCA shares. Stifel Nicolaus reiterated a “buy” rating and set a $24.00 price target on shares of Tocagen in a report on Tuesday, July 25th. Zacks Investment Research downgraded Tocagen from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th.

A hedge fund recently bought a new stake in Tocagen stock. California State Teachers Retirement System purchased a new position in shares of Tocagen Inc (NASDAQ:TOCA) in the second quarter, according to its most recent filing with the SEC. The firm purchased 14,900 shares of the company’s stock, valued at approximately $179,000. California State Teachers Retirement System owned 0.09% of Tocagen at the end of the most recent quarter. 37.85% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Tocagen Inc (TOCA) Announces Earnings Results” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at

Tocagen Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with's FREE daily email newsletter.